Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Segment Revenue
Recognized revenue	[1]	$ 60,864	$ 64,513
Segment Adjusted EBITDA
Total Adjusted EBITDA		(49,800)	(49,715)
Net loss		(104,624)	(89,532)
Adjustments
Interest income, net		(4,307)	(245)
Other income (expense), net		(333)	435
Income tax benefit		0	(254)
Depreciation and amortization		4,478	5,104
Amortization of acquired intangible assets		3,638	4,315
Stock-based compensation expense		51,100	30,462
Transaction-related costs	[2]	248
Total Adjusted EBITDA		(49,800)	(49,715)
Consumer And Research Services
Segment Revenue
Recognized revenue	[1]	60,864	64,513
Segment Adjusted EBITDA
Total Adjusted EBITDA		(5,602)	(16,997)
Therapeutics
Segment Adjusted EBITDA
Total Adjusted EBITDA		(31,138)	(18,465)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	[3]	$ (13,060)	$ (14,253)

[1] There was no Therapeutics revenue for the three months ended June 30, 2023 and 2022.

[2] Refer to Note 17, “Subsequent Events” for additional information

[3] Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.